Work

Supplementary Figure S1 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Kaplan-Meier estimates of Progression-free survival (A) and Overall survival (B) in ICI refractory and relapsed patients.

DOI: 10.1158/1078-0432.22471761

Authors: Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott J. Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, Kristen Goas, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A. Beg

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362406609

Cites:

Cited by:

Related to: 10